[Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis].

Q3 Medicine

Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova Pub Date : 2025-01-01 DOI:10.17116/jnevro202512502169

F I Devlikamova, D R Safina

{"title":"[Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis].","authors":"F I Devlikamova, D R Safina","doi":"10.17116/jnevro202512502169","DOIUrl":null,"url":null,"abstract":"Objective: To determine the efficacy and safety of Actitropil (fonturacetam) in asthenia.Material and methods: This meta-analysis includes the studies results on fonturacetam efficacy in asthenia. After checking for the risk of bias and the risk of systematic errors, the meta-analysis included 11 articles. The efficacy and safety of fonturacetam at a daily dose of 200 mg was assessed, since patients received this dose in all included studies.Results: The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1-53.7). In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85-23.85 points) (p<0.0001). Additional effects of fonturacetam: positive effect on emotional background, sleep, cognitive functions, quality of life. High patient satisfaction with treatment was observed. During treatment with fonturacetam, the frequency of side effects averaged 5.5%. Side effects were transient and completely regressed within a week of continued treatment.Conclusion: Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 2","pages":"69-79"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/jnevro202512502169","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determine the efficacy and safety of Actitropil (fonturacetam) in asthenia.

Material and methods: This meta-analysis includes the studies results on fonturacetam efficacy in asthenia. After checking for the risk of bias and the risk of systematic errors, the meta-analysis included 11 articles. The efficacy and safety of fonturacetam at a daily dose of 200 mg was assessed, since patients received this dose in all included studies.

Results: The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1-53.7). In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85-23.85 points) (p<0.0001). Additional effects of fonturacetam: positive effect on emotional background, sleep, cognitive functions, quality of life. High patient satisfaction with treatment was observed. During treatment with fonturacetam, the frequency of side effects averaged 5.5%. Side effects were transient and completely regressed within a week of continued treatment.

Conclusion: Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.

查看原文本刊更多论文

[氟图西坦治疗衰弱的疗效和安全性：一项系统综述和荟萃分析]。

目的：探讨曲托必（福图西坦）治疗衰弱症的疗效和安全性。材料与方法：本荟萃分析包括有关氟图西坦治疗乏力疗效的研究结果。在检查偏倚风险和系统错误风险后，meta分析纳入了11篇文章。评估了日剂量为200mg的氟图西坦的疗效和安全性，因为在所有纳入的研究中患者都接受了该剂量。结果：meta分析纳入549例患者（平均年龄45.9岁，95% CI: 38.1-53.7）。在所有的研究中，根据MFI-20量表，在氟图西坦治疗一个疗程（一个月疗程，治疗开始后第30天评估）后，衰弱水平显著降低，平均降低16.3分（95% CI: 8.85-23.85分）(p结论：氟图西坦治疗一个月后有效降低衰弱综合征水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova 医学-精神病学

CiteScore

1.10

自引率

0.00%

发文量

287

审稿时长

3-6 weeks

期刊介绍： Одно из старейших медицинских изданий России, основанное в 1901 году. Создание журнала связано с именами выдающихся деятелей отечественной медицины, вошедших в историю мировой психиатрии и неврологии, – С.С. Корсакова и А.Я. Кожевникова. Широкий диапазон предлагаемых журналом материалов и разнообразие форм их представления привлекают внимание научных работников и врачей, опытных и начинающих медиков, причем не только неврологов и психиатров, но и специалистов смежных областей медицины.